Design, Characterization, and Use of a Novel Amyloid β-Protein Control for Assembly, Neurotoxicity, and Gene Expression Studies.

@article{Yamin2016DesignCA,
  title={Design, Characterization, and Use of a Novel Amyloid $\beta$-Protein Control for Assembly, Neurotoxicity, and Gene Expression Studies.},
  author={Ghiam Yamin and Giovanni Coppola and David B. Teplow},
  journal={Biochemistry},
  year={2016},
  volume={55 36},
  pages={
          5049-60
        }
}
A key pathogenic agent in Alzheimer's disease (AD) is the amyloid β-protein (Aβ), which self-assembles into a variety of neurotoxic structures. Establishing structure-activity relationships for these assemblies, which is critical for proper therapeutic target identification and design, requires aggregation and neurotoxicity experiments that are properly controlled with respect to the Aβ peptide itself. "Reverse" Aβ or non-Aβ peptides suffer from the fact that their biophysical properties are… 
View on PubMed
escholarship.org
4 Citations
Background Citations
1
Methods Citations
2

4 Citations

Citation Type

Citation Type

Hetero-assembly of a dual β-amyloid variant peptide system.
TLDR
This study reports the creation of a dual peptide system, where a pair of β-amyloid (Aβ) variants are not self-assembled but hetero-assembled in the presence of their assembly partners, and provides evidence that the resultinghetero-assemblies share molecular, structural and morphological similarities with typical amyloid self- assemblies formed by a single polypeptide.
An extensive plasmid library to prepare tau protein variants and study their functional biochemistry.
TLDR
The plasmid library, the protein production methods, and the new insights into cysteine-dependent aggregation, should facilitate further studies and the design of anti-aggregation agents.
Activated Bone Marrow-Derived Macrophages Eradicate Alzheimer's-Related Aβ42 Oligomers and Protect Synapses
TLDR
It is found that cortical neurons were more susceptible to Aβ42 oligomers than fibrils, triggering additional neuritic arborization retraction, functional alterations, and loss of VGluT1- and PSD95-excitatory synapses, providing rationale for harnessing macrophages to treat AD.
Absence of Pannexin 1 Stabilizes Hippocampal Excitability After Intracerebral Treatment With Aβ (1-42) and Prevents LTP Deficits in Middle-Aged Mice
TLDR
The data show that in the absence of Pannexin1, hippocampi are more resistant to the debilitating effects of oligomeric Aβ, and both Aβ-mediated impairments in spike frequency adaptation and in LTP that occur in wt animals, are ameliorated in Panx1-ko mice.

References

SHOWING 1-10 OF 52 REFERENCES
Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways
TLDR
PICUP, size-exclusion chromatography, dynamic light scattering, circular dichroism spectroscopy, and electron microscopy have been combined to elucidate fundamental features of the early assembly of Aβ40 and Aβ42, demonstrating that A β42 assembly involves formation of several distinct transient structures that gradually rearrange into protofibrils.
Structure‐Activity Relationships for a Series of Compounds that Inhibit Aggregation of the Alzheimer's Peptide, Aβ42
TLDR
The ability of a compound to inhibit Aβ aggregation was a good predictor of its efficacy in prolonging the life span and locomotive ability of transgenic flies expressing human Aβ42 in the central nervous system.
Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β
TLDR
The identification and characterization of ASPD is described and its possible role in the neurodegeneration in Alzheimer's disease is discussed and inhibition experiments with lithium suggest the involvement of tau protein kinase I/glycogen synthase kinase-3β in the early stages of ASD-induced neurodegenersation.
Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability*
TLDR
Data demonstrate that protocols developed to produce oligomeric and fibrillar Aβ-(1–42) are useful in distinguishing the structural and functional differences between A β-(1-42) and Aβ-1–40 and genetic mutations of Aβ.
Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.
Alzheimer's disease is characterized by extensive cerebral amyloid deposition. Amyloid deposits associated with damaged neuropil and blood vessels contain abundant fibrils formed by the amyloid…
Aβ-globulomers are formed independently of the fibril pathway
Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein.
TLDR
The three N-terminal amino acid differences between Pm(1-40) and Ro(1 -40) had virtually no effect on the morphology or organization of the fibrils formed by these peptides, indicating that the lack of amyloid deposits in rodent brain is not due directly to specific changes in its beta/A4 sequence.
Amyloid β-protein oligomers and Alzheimer’s disease
TLDR
The results of in vivo, in vitro and in silico studies of amyloid β-protein oligomers are reviewed, and important caveats are discussed that should be considered in the evaluation of these results.
Aβ Oligomers – a decade of discovery
TLDR
Accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury in Alzheimer’s disease.
The Cell-Selective Neurotoxicity of the Alzheimer's Aβ Peptide Is Determined by Surface Phosphatidylserine and Cytosolic ATP Levels. Membrane Binding Is Required for Aβ Toxicity
TLDR
The response to Aβ by the cells with high Aβ binding affinity was characterized by a larger calcium response and increased mortality, lactate dehydrogenase release, caspase activation, and DNA fragmentation, and the distinctive sensitivity or resistance of the different subpopulations was maintained even after multiple cell divisions.
...
1
2
3
4
5
...